HK1213885A1 - 作為 抑制劑的咪唑並-三嗪衍生物 - Google Patents

作為 抑制劑的咪唑並-三嗪衍生物

Info

Publication number
HK1213885A1
HK1213885A1 HK16101771.5A HK16101771A HK1213885A1 HK 1213885 A1 HK1213885 A1 HK 1213885A1 HK 16101771 A HK16101771 A HK 16101771A HK 1213885 A1 HK1213885 A1 HK 1213885A1
Authority
HK
Hong Kong
Prior art keywords
pde10
imidazo
triazine derivatives
inhibitors
pde10 inhibitors
Prior art date
Application number
HK16101771.5A
Other languages
English (en)
Inventor
．查皮
．赫拉爾
．科莫斯
．塔特爾
．費爾赫斯特
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of HK1213885A1 publication Critical patent/HK1213885A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
HK16101771.5A 2013-05-02 2016-02-18 作為 抑制劑的咪唑並-三嗪衍生物 HK1213885A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361818650P 2013-05-02 2013-05-02
PCT/IB2014/060945 WO2014177977A1 (en) 2013-05-02 2014-04-23 Imidazo-triazine derivatives as pde10 inhibitors

Publications (1)

Publication Number Publication Date
HK1213885A1 true HK1213885A1 (zh) 2016-07-15

Family

ID=50841902

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16101771.5A HK1213885A1 (zh) 2013-05-02 2016-02-18 作為 抑制劑的咪唑並-三嗪衍生物

Country Status (34)

Country Link
US (3) US8933224B2 (zh)
EP (1) EP2991989B1 (zh)
JP (1) JP6263606B2 (zh)
KR (1) KR101770905B1 (zh)
CN (1) CN105164134B (zh)
AP (1) AP2015008843A0 (zh)
AR (1) AR096161A1 (zh)
AU (1) AU2014261070A1 (zh)
BR (1) BR112015027760A8 (zh)
CA (1) CA2910759C (zh)
CL (1) CL2015003037A1 (zh)
CR (1) CR20150591A (zh)
CU (1) CU20150144A7 (zh)
DK (1) DK2991989T3 (zh)
DO (1) DOP2015000271A (zh)
EA (1) EA027936B1 (zh)
EC (1) ECSP15050110A (zh)
ES (1) ES2637816T3 (zh)
GE (1) GEP201706675B (zh)
HK (1) HK1213885A1 (zh)
MA (1) MA38559B1 (zh)
MD (1) MD20150103A2 (zh)
MX (1) MX2015015163A (zh)
NI (1) NI201500157A (zh)
NZ (1) NZ712949A (zh)
PE (1) PE20151940A1 (zh)
PH (1) PH12015502462A1 (zh)
SG (1) SG11201508201VA (zh)
TN (1) TN2015000490A1 (zh)
TW (1) TWI508966B (zh)
UA (1) UA111696C2 (zh)
UY (1) UY35547A (zh)
WO (1) WO2014177977A1 (zh)
ZA (1) ZA201508968B (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2637816T3 (es) * 2013-05-02 2017-10-17 Pfizer Inc. Derivados de imidazo-triazina como inhibidores de PDE10
MX2019002797A (es) 2016-09-09 2019-05-09 Novartis Ag Compuestos y composiciones como inhibidores de los receptores endosomales tipo peaje.
WO2021080312A1 (ko) * 2019-10-21 2021-04-29 에스케이바이오팜 주식회사 인지 장애의 예방, 경감 또는 치료, 또는 인지 기능 향상을 위한 이미다조피리미딘 또는 이미다조트리아진 화합물의 용도

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010007867A1 (en) 1999-12-13 2001-07-12 Yuhpyng L. Chen Substituted 6,5-hetero-bicyclic derivatives
DE10130167A1 (de) 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
DE10230604A1 (de) 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
US20070032404A1 (en) 2003-07-31 2007-02-08 Bayer Pharmaceuticals Corporation Methods for treating diabetes and related disorders using pde10a inhibitors
JP4559749B2 (ja) * 2004-02-16 2010-10-13 あすか製薬株式会社 ピペラジニルピリジン誘導体
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
US20070167426A1 (en) 2004-06-02 2007-07-19 Schering Corporation Compounds for the treatment of inflammatory disorders and microbial diseases
TW200716102A (en) 2005-06-01 2007-05-01 Wyeth Corp Bicyclic 6-alkylidene-penems as class-D β -lactamases inhibitors
US20080051419A1 (en) 2006-07-26 2008-02-28 Pfizer Inc. Amine derivatives useful as anticancer agents
WO2008041571A1 (fr) 2006-09-26 2008-04-10 Kaneka Corporation Procédé de fabrication d'un ester d'acide bêta-hydroxy-alpha-aminocarboxylique optiquement actif
WO2008057402A2 (en) 2006-11-02 2008-05-15 Cytovia, Inc. N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof
WO2009025785A2 (en) 2007-08-21 2009-02-26 Merck & Co., Inc. Cb2 receptor ligands for the treatment of pain
DE102007059723A1 (de) 2007-12-12 2009-06-18 Siemens Medical Instruments Pte. Ltd. Hörvorrichtung mit Batterieklappenmodul
PE20091057A1 (es) 2007-12-19 2009-07-20 Lilly Co Eli Antagonistas del receptor mineralcorticoide y metodos de uso
CA2716856C (en) 2008-03-20 2013-02-19 Amgen Inc. Aurora kinase modulators and method of use
CA2778949C (en) * 2009-10-30 2018-02-27 Janssen Pharmaceutica Nv Imidazo[1,2-b]pyridazine derivatives and their use as pde10 inhibitors
CA2787714C (en) 2010-01-22 2019-04-09 Joaquin Pastor Fernandez Inhibitors of pi3 kinase
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
WO2011141713A1 (en) 2010-05-13 2011-11-17 Centro Nacional De Investigaciones Oncologicas (Cnio) New bicyclic compounds as pi3-k and mtor inhibitors
CA2799926A1 (en) 2010-05-28 2011-12-01 Biocryst Pharmaceuticals, Inc. Heterocyclic compounds as janus kinase inhibitors
JP2013532149A (ja) 2010-06-17 2013-08-15 ノバルティス アーゲー ピペリジニル置換１，３−ジヒドロ−ベンゾイミダゾール−２−イリデンアミン誘導体
JP5543039B2 (ja) * 2011-02-23 2014-07-09 ファイザー・インク 神経障害治療のためのイミダゾ［５，１−ｆ］［１，２，４］トリアジン
ES2637816T3 (es) * 2013-05-02 2017-10-17 Pfizer Inc. Derivados de imidazo-triazina como inhibidores de PDE10

Also Published As

Publication number Publication date
AP2015008843A0 (en) 2015-11-30
EP2991989A1 (en) 2016-03-09
KR20160003234A (ko) 2016-01-08
BR112015027760A8 (pt) 2018-05-08
SG11201508201VA (en) 2015-11-27
EA027936B1 (ru) 2017-09-29
CU20150144A7 (es) 2016-04-25
MX2015015163A (es) 2016-02-22
AR096161A1 (es) 2015-12-09
AU2014261070A1 (en) 2015-10-29
ZA201508968B (en) 2017-11-29
ES2637816T3 (es) 2017-10-17
CN105164134A (zh) 2015-12-16
NI201500157A (es) 2015-11-30
US20140329820A1 (en) 2014-11-06
US8933224B2 (en) 2015-01-13
JP2016517877A (ja) 2016-06-20
CR20150591A (es) 2016-01-04
KR101770905B1 (ko) 2017-08-23
CA2910759C (en) 2018-01-16
TW201506027A (zh) 2015-02-16
US20150353579A1 (en) 2015-12-10
CN105164134B (zh) 2017-09-22
WO2014177977A1 (en) 2014-11-06
CA2910759A1 (en) 2014-11-06
MD20150103A2 (ro) 2016-02-29
GEP201706675B (en) 2017-05-25
DK2991989T3 (en) 2017-07-31
TWI508966B (zh) 2015-11-21
PE20151940A1 (es) 2016-01-21
UY35547A (es) 2014-11-28
JP6263606B2 (ja) 2018-01-17
MA38559B1 (fr) 2018-04-30
UA111696C2 (uk) 2016-05-25
ECSP15050110A (es) 2017-08-31
EA201591819A1 (ru) 2016-05-31
PH12015502462A1 (en) 2016-02-22
EP2991989B1 (en) 2017-06-28
US9145427B2 (en) 2015-09-29
US20150080401A1 (en) 2015-03-19
CL2015003037A1 (es) 2016-04-22
TN2015000490A1 (fr) 2017-04-06
US9296761B2 (en) 2016-03-29
DOP2015000271A (es) 2016-02-29
NZ712949A (en) 2017-04-28

Similar Documents

Publication Publication Date Title
HRP20190373T1 (hr) Inhibitori dnk-pk
HK1222646A1 (zh) 作為溴結構域抑制劑的苯並咪唑衍生物
PL3057959T3 (pl) Inhibitory DNA-PK
HK1220459A1 (zh) 激酶抑制劑
HK1211578A1 (zh) 作為 激酶抑制劑的酰氨基咪唑並噠嗪
HK1223090A1 (zh) -氮雜吲哚衍生物
HK1216531A1 (zh) 新的抑制劑
HK1219104A1 (zh) 激酶抑制劑
IL246230A0 (en) Amines thf quinazoline as pde1 inhibitors
HK1213885A1 (zh) 作為 抑制劑的咪唑並-三嗪衍生物
EP2968324A4 (en) SUBSTITUTED PYRIDONE DERIVATIVES AS PDE10 INHIBITORS
HK1226072A1 (zh) 作為bcl-3抑制劑的2-苯甲酰氨基苯甲酰胺衍生物
HK1204617A1 (zh) 作為 抑制劑的***並化合物
GB201307155D0 (en) Kinase inhibitors

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20220421